Does consolidation durvalumab increase the risk of pneumonitis in Stage III NSCLC?

Given the heterogeneity of pneumonitis presentation, the presence of pre-checkpoint inhibitor chest/mediastinal irradiation (by definition in this trial), and the other risk factors often seen in this population (COPD/emphysema, current/past smoking history), it is a real challenge to decipher pulmo...

I’m seeing slightly higher incidence of pneumonitis in my practice than PACIFIC trial.